• Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • NP and PA
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
  • Vitiligo
  • Wound Care

Article

Progressing Skin Penetration

Stanford, Calif. - Conjugation of cyclosporin A to arginine oligomer protein transduction sequences provides a promising method for delivery of the peptide immunosuppressant agent into psoriatic skin. However, further study is needed to characterize the cutaneous bioavailability achieved with that novel delivery platform and to answer the larger question of whether topical cyclosporin A offers a viable therapeutic modality for psoriasis, according to David F. Fiorentino, M.D., Ph.D.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

© 2025 MJH Life Sciences

All rights reserved.